Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > The Bracelet-1 90 day exclusivity should be over x Feb 2023

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Nov 27, 2022 7:41pm

232 Views

Post# 35132506

RE:RE:RE:The Bracelet-1 90 day exclusivity should be over x Feb 2023

Now it's early March at the latest? Seems the only ones with definitive answers on this front are presently in negotiations. I guess the 90 day exclusivity doesn't really matter after Roche makes an offer in the coming weeks.

<< Previous

Bullboard Posts

Next >>

Mining companies take action on reconciliation with First Nations